Effect of Nasal CPAP Versus NIPPV On Diaphragm Electrical Activity (Edi) In VLBW Preterm Infants
Effect of Nasal Continuous Positive Airway Pressure (nCPAP) Versus Non-Invasive Positive Pressure Ventilation (NIPPV) On Diaphragm Electrical Activity (Edi) In Very Low Birth Weight (VLBW) Preterm Infants
1 other identifier
interventional
24
1 country
1
Brief Summary
Background: In premature babies, many organ systems are not fully grown and developed, including the lungs and respiratory muscles, so they will need breathing support to help them to breathe by preventing their tiny air sacs to collapse. This support commonly done by CPAP and Non-Invasive Positive Pressure Ventilation (NIPPV) therapy by giving some pressure and oxygen to their lungs through an interface placed on their noses. Both (CPAP and NIPPV) can be used as a support modality for respiratory distress syndrome, apnea of prematurity, and providing breathing support after extubation from the full mechanical breathing support. The CPAP supports the baby's immature lungs by delivering constant pressure to keep their lungs and breathing well supported. Whereas the NIPPV will use constant pressure in the background (similar to CPAP), and on top, it will give extra intermittent puffs at regular intervals to support the baby's breathing. The NIPPV is the most common choice by the clinicians when the traditional CPAP is no longer effective, to avoid the full mechanical breathing support and to protect the developing lungs. Studies suggested that NIPPV is better than the traditional CPAP in reducing the need of the baby to need full mechanical breathing support. This might be because the investigators tend to use lower pressures with CPAP (5-8 cmH2O) compared to relatively higher pressures with NIPPV. More recently, clinicians showed the safety of using equivalent higher CPAP pressures (\>9 cmH2O) to what the investigators use in the NIPPV in preterm babies. One way to measure the support that the investigators are giving to the patient with the different devices is to measure the diaphragm activity, which the investigators call the Edi signal, using a special feeding catheter and a specific machine to measure it. The catheter is placed and used as a routine feeding tube but has sensors at the end to measure this Edi signal. One opening of the tube will be connected to a computer to record the Edi signals. The other opening of the tube will be used for feeding.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Aug 2021
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 21, 2021
CompletedFirst Submitted
Initial submission to the registry
February 20, 2024
CompletedFirst Posted
Study publicly available on registry
March 6, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
ExpectedMarch 6, 2024
February 1, 2024
4.4 years
February 20, 2024
March 5, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
The differences in Electrical Activity of the Diaphragm measured in MicroVoltage (Edi minimum) between: 1. Traditional CPAP versus NIPPV. 2. NIPPV versus CPAP (equivalent pressures in cmH2O).
2 hours per each mode of ventilation, total of 6 hours Edi recording
Secondary Outcomes (4)
1. Neural respiratory rate per minute
2 hours per each mode of ventilation, total of 6 hours
2. Edi peak measured in MicroVoltage
2 hours per each mode of ventilation, total of 6 hours
3. The difference in transcutaneous pCO2 in mmHg
2 hours per each mode of ventilation, total of 6 hours
4. The difference in oxygen requirements in percent (i.e, 21%)
2 hours per each mode of ventilation, total of 6 hours
Study Arms (6)
Traditional CPAP, then NIPPV, then high CPAP.
OTHERThe participant will stay for 2 hours on Traditional CPAP, then 2 hours on NIPPV, then 2 hours on high CPAP. The investigators will continue to record the Edi signals during the 3 methods.
Traditional CPAP, then high CPAP, then NIPPV
OTHERThe participant will stay for 2 hours on Traditional CPAP, then 2 hours on high CPAP, then 2 hours on NIPPV. The investigators will continue to record the Edi signals during the 3 methods.
NIPPV, then traditional CPAP, then high CPAP
OTHERThe participant will stay for 2 hours on NIPPV, then 2 hours on traditional CPAP, then 2 hours on high CPAP. The investigators will continue to record the Edi signals during the 3 methods.
NIPPV, then high CPAP, then traditional CPAP.
OTHERThe participant will stay for 2 hours on NIPPV, then 2 hours on high CPAP, then 2 hours on traditional CPAP. The investigators will continue to record the Edi signals during the 3 methods.
High CPAP, then traditional CPAP, then NIPPV.
OTHERThe participant will stay for 2 hours on High CPAP, then 2 hours on traditional CPAP, then 2 hours on NIPPV. The investigators will continue to record the Edi signals during the 3 methods.
High CPAP, then NIPPV, then traditional CPAP.
OTHERThe participant will stay for 2 hours on High CPAP, then 2 hours on NIPPV, then 2 hours on traditional CPAP. The investigators will continue to record the Edi signals during the 3 methods.
Interventions
The investigators will continue to record the Edi signals during the 3 methods (traditional CPAP, NIPPV, and high CPAP)
Eligibility Criteria
You may qualify if:
- Clinically stable preterm infants (defined as cardiovascular stability with normal blood pressure and heart rate for gestational age and no recent increase in apneic episodes or spells and confirmed by the attending neonatologist)
- Birth weight less than 1500 grams
- Admitted to the NICU at Sunnybrook Health Sciences Centre on nasal CPAP of 5 to 8 cmH2O support, for at least 48 hours and requiring less than 35% of oxygen
You may not qualify if:
- Congenital anomalies of the gastrointestinal tract
- Phrenic nerve damage
- Diaphragmatic paralysis
- Esophageal perforation
- Congenital or acquired neurological deficit (including significant intraventricular hemorrhage greater than Grade II) or neonatal seizure
- Significant congenital heart disease (including symptomatic PDA)
- Congenital anomalies of the diaphragm
- Congenital anomalies of the respiratory tracts (e.g., Congenital Cystic Adenomatoid Malformation 'CCAM')
- Ongoing treatment for sepsis
- Ongoing treatment for necrotizing enterocolitis (NEC)
- Ongoing treatment for lung infections
- Narcotic analgesics
- Gastric motility agents
- Infants on nasal CPAP and requiring more than 35% oxygen
- Infants with significant gastric residuals and vomiting
- +3 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Sunnybrook Health Sciences Center
Toronto, Ontario, M4N 3M5, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 20, 2024
First Posted
March 6, 2024
Study Start
August 21, 2021
Primary Completion
December 31, 2025
Study Completion (Estimated)
December 31, 2026
Last Updated
March 6, 2024
Record last verified: 2024-02
Data Sharing
- IPD Sharing
- Will not share